AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05784012 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin plus radiotherapy
Description: In the concurrent phase
Study NCT05784012 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib
Description: Niraparib 200 or 300mg orally administered QD (Neoadjuvant and Maintenance stages).
Study NCT05104060 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: pectoralis minor intervention group
Description: The subjects in pectoralis minor group will received manual therapy for pectoralis minor by physical therapist, the technique including stretch and soft tissue mobilization. The subjects asked to perform the scapular control exercise and shoulder strength exercise.Subjects will be correct scapular resting position and then do elevation in scapular plane.Four exercises for shoulder strength will do shoulder flexion, abduction, internal and external rotation with thera-band.
Study NCT05104060 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: shoulder strengthening group
Description: The subjects in the scapular strengthening group will be asked to do four exercises for shoulder strength, including shoulder flexion, abduction, internal and external rotation with thera-band.
Study NCT05326737 — intervention group
Intervention type: OTHER
Intervention: In hospital pain evaluation
Description: Patients will evaluate their pain levels via a verbal numerical scale on days 1(or-1), 2, 3, 4, 5, 6 \& 7.
Study NCT05326737 — intervention group
Intervention type: OTHER
Intervention: In hospital questionnaires
Description: Patients are required to fill out the PCS questionnaire between on day -1 or +1.
Study NCT05326737 — intervention group
Intervention type: OTHER
Intervention: Telephone contact at 3 months
Description: Patients will be contacted at 3 months post-surgery for pain questionnaires DN4 and EQ5D5L.
Study NCT04811521 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Primary care follow-up
Description: Those randomized to primary care and enhanced primary care coordination will receive the minimal intensity treatment that includes: (1) assistance in identifying a primary care provider for participants who do not have one, (2) sharing results of diagnostic testing (including anxiety screening) with the primary care provider (results sent via EMR note, mailed letter, or delivered by participant at appointment); and (3) an educational brochure on anxiety and treatment.
Study NCT04811521 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Online Self-Administered Anxiety Management Program plus Peer Support Guidance
Description: Individuals randomized to the online Cognitive Behavioral Therapy (CBT) + peer support guidance arm will receive access to six online, evidence-based CBT modules in the This Way Up Generalized Anxiety Course to be completed weekly or bi-monthly. Individuals who screen positive on the PHQ panic measure will complete 2 additional panic-specific homework assignments applying exposure therapy to panic (in addition to Generalized Anxiety Disorder) experiences aligned with content from the This Way Up Panic Course.
Study NCT04811521 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Therapist-Administered Cognitive Behavioral Therapy
Description: Individuals randomized to therapist-led CBT via telehealth will receive 8 one-hour sessions over the course of 8 to 10 weeks via telehealth (HIPAA compliant software such as Zoom Health or AmWell) or telephone. Therapists will be master's-degreed or eligible clinicians trained in CBT by our study psychologist. Therapists will follow a manualized protocol for delivering CBT for anxiety, specifically, with a primary focus on anxiety and worry management. Individuals who screen positive on the PHQ panic measure will have training in exposure therapy added to CBT. Although many CBT trials have a standard length of 12 sessions, brief CBT lasting 4-8 sessions is equally efficacious.
Study NCT06448312 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SKB264
Description: IV Infusion
Study NCT06448312 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: IV Infusion
Study NCT06448312 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV Infusion
Study NCT06241599 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GP/PFLL+AK104
Description: Groups 1 and 2: Patients who have not been treated with PFLL in front-line therapy. 5-Fu:200mg/m2/d, d1-30, continuous intravenous infusion; Cisplatin: 80mg/m2, intravenous infusion for 4h, the first and 28th days of each cycle; AK104: 6mg/kg intravenous infusion for more than 60 minutes, used on days 1, 15, 30, 45 of each cycle, and administered 30 minutes before chemotherapy drugs during chemotherapy.~Groups 3 and 4: Patients who had never used GP in their front-line treatment regimen. Gemcitabine: 1000mg/m2, used on the 1st and 8th day of each cycle; Cisplatin: 80mg/m2 on the first day of each cycle; AK104 6mg/kg intravenous infusion for more than 60 minutes was used on day 1, 15 (single cycle)/or day 8 (double cycle) of each cycle, and was administered 30 minutes before chemotherapy drugs during chemotherapy. Every 3 weeks is a treatment cycle, with a maximum of 6 cycles used. After 6 cycles of chemotherapy, both groups could continue to receive AK104 (once every 2 weeks).
Study NCT06241599 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: GP/PFLL+placebo
Description: Groups 1 and 2: Patients who have not been treated with PFLL in front-line therapy. 5-Fu:200mg/m2/d, d1-30, continuous intravenous infusion; Cisplatin: 80mg/m2, intravenous infusion for 4h, the first and 28th days of each cycle; placebo: 6mg/kg intravenous infusion for more than 60 minutes, used on days 1, 15, 30, 45 of each cycle, and administered 30 minutes before chemotherapy drugs during chemotherapy.~Groups 3 and 4: Patients who had never used GP in their front-line treatment regimen. Gemcitabine: 1000mg/m2, used on the 1st and 8th day of each cycle; Cisplatin: 80mg/m2 on the first day of each cycle; placebo 6mg/kg intravenous infusion for more than 60 minutes was used on day 1, 15 (single cycle)/or day 8 (double cycle) of each cycle, and was administered 30 minutes before chemotherapy drugs during chemotherapy. Every 3 weeks is a treatment cycle, with a maximum of 6 cycles used. After 6 cycles of chemotherapy, both groups could continue to receive placebo (once every 2 weeks).
Study NCT04980846 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Driving under the influence of alcohol with a driving simulator
Description: Participants will drive in three different states (sober, drunk above and below the legal limit) on designated circuits using a driving simulator. After the initial sober driving session, participants are administered pre-mixed alcoholic beverages (e.g., vodka orange). Participants are expected to achieve a target BrAC of 0.35 mg/l (legal limit in Switzerland is 0.25 mg/l BrAC) before the second driving session starts. Finally, the third driving session starts when the participants' BrAC drops to 0.15 mg/l. Heart rate, skin conductance, accelerometer, eye movement, radar, facial expression, and speech will be recorded by a smart-watch, an eye-tracker, microphones and an onboard camera, respectively.~Participants will be blinded to their alcohol levels during the study. They will have to rate their symptoms and their performance via questionnaires before and after each driving session. Further, capillary blood and oral fluid samples will be collected.
Study NCT05623904 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Carotid Revascularization
Description: Carotid Artery Stenting/Carotid Endarterectomy
Study NCT05623904 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Medical Treatment
Description: Aspirin 100mg/ day plus clopidogrel 75mg/ day for the first three months after enrollment or revascularization, aspirin 100mg/ day after three months, and the statin dose was adjusted according to blood lipids levels. Best medical treatment also includes risk factor control: good lifestyle, smoking cessation, weight control, regular exercise, SBP \< 140 mmHg, HDL \< 70 mg/dl (1.8mmol/L), and glycemic control. Patients with poor control of risk factors were dynamically adjusted during follow-up.~In addition, patients undergoing CAS received dual antiplatelet therapy for at least 3 to 5 days before surgery, and patients undergoing CEA also received a preoperative oral antiplatelet drug (aspirin 100mg/ day, or clopidogrel 75mg/ day) for at least 3 days after enrollment.
Study NCT06122428 — intervention group
Intervention type: DRUG
Intervention: modified hyaluronic acid 0.1% covalently linked to Riboflavin
Description: The patients used the eye drops no less than 3 times a day or no more than 6 times a day, according to their needs. They reported the instillation frequency (3/4 or 5/6 times per day) on the provided document
Study NCT06122428 — intervention group
Intervention type: DRUG
Intervention: hyaluronic acid 0.1%
Description: The patients used the eye drops no less than 3 times a day or no more than 6 times a day, according to their needs. They reported the instillation frequency (3/4 or 5/6 times per day) on the provided document
Study NCT04901065 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xylocaine
Description: The study intervention was the administration of 10 mg of intranasal lidocaine in one nostril using 1 spray of 0.1mL of a 10% lidocaine solution 5 minutes before NPS. This was done using the standard long nozzle
Study NCT04901065 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Placebo
Description: The control group received the placebo with the same application technique using an empty bottle of lidocaine 10% with the same long nozzle for delivery
Study NCT05445011 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine + Cyclophosphamide + TAA05 Cell Injection
Description: Fludarabine + Cyclophosphamide + TAA05 Cell Injection Fludarabine 25 mg/kg \* 3d on day-7\~-2; Cyclophosphamide 250 mg/kg \*3d on day-7\~-2; TAA05 Cell Injection on day 0.
Study NCT05491057 — intervention group
Intervention type: DRUG
Intervention: Neratinib
Description: Neratinib standard dose 240 mg once daily for 1 year
Study NCT06212167 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nursing Interventions for Stroke Patient Care
Description: In the first phase of the research, the relatives of the patients who are in the hospital every day for a week during the routine and discharge process will be included in a training program. These trainings will be explained didactically to the caregiver at the bedside by the research supervisor and the intensive care nurse, the practices will be demonstrated with demonstrations, and the caregiver will be asked to apply them themselves. Then, the researchers will call the caregivers and make an appointment for an online meeting twice a week (7 weeks - 14 times). During these meetings, the training the caregivers need will be explained again and any questions they have will be answered. The researcher will also conduct motivational interviews with the caregivers.
Study NCT05372380 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BR1017-1
Description: Administration to the F/F+AE group: BR1017-1 will be administered 1 tablet QD, five-day repeat dose
Study NCT06270693 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endodontic treatment
Description: Root canal treatment
Study NCT05056454 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online therapy with coaching within STAND
Description: Participants with moderate depressive symptoms on the CAT-MH (and no current suicidality) will meet with a trained coach, and receive access to online course materials from one of 2 lesson platforms - ThisWayUp's MUMentum course or UCLA DGC's ParentMood course. The efficacy of each online course will be compared for equivalency.~Participants are encouraged to practice their lesson homework for at least one week before meeting with their coach and starting the next lesson.
Study NCT05056454 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Clinical care within STAND
Description: Participants with severe depressive symptoms or significant suicidality on the CAT-MH will be allocated to access clinical care, which entails weekly psychotherapy sessions and psychiatric care, when needed or appropriate. While clinical care will be available for the entire 6-month duration of the treatment component of the study, participants will be informed that on average therapy is completed within 13 sessions. The schedule of psychiatric care will be determined by the provider.
Study NCT05056454 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Perinatal Psychiatric Care
Description: Perinatal psychiatric care involves medication management and supportive therapy for up to six months, with referrals to relevant community resources by the final visit.
Study NCT04891991 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravitreal infliximab
Description: 1 mg/0.05 mL of infliximab will be injected intravitreally at the end of pars plana vitrectomy.
Study NCT04891991 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pars plana vitrectomy
Description: Standard pars plana vitrectomy
Study NCT05372380 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BR1017-2
Description: Administration to the AE group: BR1017-2 will be administered 1 tablet QD, 9-day repeat dose Administration to the F+AE group: BR1017-2 will be administered 1 tablet once QD, 5-day repeat dose.
Study NCT04891991 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Pars plana vitrectomy
Description: Standard pars plana vitrectomy
Study NCT05628181 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational nudge intervention
Description: This project will adapt the EMPOWER educational brochure for PLWD receiving CNS polyRx. The educational brochure will be mailed to intervention participants identified through EHR at Michigan Medicine and Henry Ford Health System. The brochure will describe what CNS polyRx is, present information about the associated risks, and suggest that participants speak with the prescribing clinician or pharmacist about ways to potentially simplify the medication regimen. The tool will be adapted through three successive rounds of focus groups (AIM one of this project) of PLWD.
Study NCT05865392 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Move physical activity support program
Description: The Move program includes four intervention components: 1) 3, 60-minute group-based classes, 2) 3, 45-minute individualized support sessions, 3) access to an online fitness membership, and 4) weekly mental guided imagery sessions. Participants will be asked to build up their physical activity levels up to 150 minutes/week. They will receive an online fitness center membership during this entire 12-week program.
Study NCT06269354 — intervention group
Intervention type: DEVICE
Intervention: 3D printed prostheses
Description: 3D printed prostheses
Study NCT05108116 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: EOS
Description: EOS Micro Dose imaging will be done. SterEOS 3D recontruction of the lower limb and pelvis will be performed.
Study NCT05126004 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: 28 days for one cycle, evaluation post 3 cycles of treatment. Continue if response exists, otherwise, quit the trial and seek for other therapies.
Study NCT05126004 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N Acetyl L Cysteine
Description: 28 days for one cycle, evaluation post 3 cycles of treatment. Continue if response exists, otherwise, quit the trial and seek for other therapies.
Study NCT06442254 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Reality
Description: In the application, which will be done with VR glasses, a video of walking on Istiklal Street in Istanbul's Beyoğlu district will be watched.
Study NCT06628856 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality of life
Description: The study proposes a 3-time longitudinal design, with evaluations at baseline, 2.5 months, and 5 months, to measure the impact of an intervention on terminally ill patients and their families, focusing on health status, quality of life, and emotional well-being.
Study NCT05601882 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Upadacitinib
Description: Oral Tablets
Study NCT04877587 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ascorbate
Description: A patient-individualized pharmacokinetically-guided dose escalation design will be used for Ascorbate. The goal of the within-patient dose escalation is to achieve a target plasma ascorbate level between 20mM and 30mM. The administered dose levels under consideration are listed below.~Dose Level Ascorbate~* 2 60 g/m2 IV Days (1,2,8,9,15,16)~* 1 50 g/m2 IV Days (1,2,8,9,15,16) 0 (Starting dose) 40 g/m2 IV Days (1,2,8,9,15,16)~  * 1 30 g/m2 IV Days (1,2,8,9,15,16)
Study NCT04877587 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine 900 mg/m2 given at a fixed dose rate of 10 mg/m2/min on D1, D8 and D15 to be given over 90 min every 28 days
Study NCT06123026 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabergoline
Description: 1mg oral cabergoline given to participants once
Study NCT06123026 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 encapsulated placebo tablet given to participants after procedure
Study NCT05310708 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Polysomnography
Description: Measuring and recording multiple physiological parameters from a patient which are used by clinicians to make a decision on the diagnosis of sleep.
Study NCT05560555 — intervention group
Intervention type: DRUG
Intervention: Tafamidis
Description: 61 milligrams (mg) as received in studies B3461028 and B3461045
Study NCT05975177 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sterify Gel
Description: A mucoadhesive polymeric hydrogel in a prefilled syringe for nonsurgical treatment of periodontal and peri-implant pockets, composed of polyvinyl polymers, hydroxytyrosol, nisin, and magnesium ascorbyl phosphate
Study NCT05975177 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Scaling and root planing
Description: The non-surgical procedure involved SRP under local anesthesia with EMS scalers and Gracey curettes.
Study NCT05975177 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Scaling and root planing
Description: The non-surgical procedure involved SRP under local anesthesia with EMS scalers and Gracey curettes.
Study NCT06239714 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SGB-3403
Description: SGB-3403 is a synthetic, chemically modified small interfering ribonucleic acid (siRNA) targeting proprotein convertase subtilisin kexin type 9 (PCSK9) messenger ribonucleic acid (mRNA) with a covalently attached triantennary N-acetylgalactosamine (GalNAc) ligand.
Study NCT06239714 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: The dosage of atorvastatin was determined by the investigator
Study NCT06239714 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Atorvastatin
Description: The dosage of atorvastatin was determined by the investigator
Study NCT06239714 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal saline 0.9%
Study NCT05305768 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IncobotulinumtoxinA
Description: Injection of glabellar rhytids
Study NCT04675775 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medically-tailored meals (MTM)
Description: After the run-in baseline period participants will be expected to consume the meals and protein supplements meals between approximately Weeks 4 - 11 of the study. Additionally, participants will complete surveys before, during and after the meals.
Study NCT04675775 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Protein supplements
Description: A daytime and nighttime protein supplement will be provided after the baseline visit and should be consumed daily at home during the same study days as MTM. The daytime protein supplement is a protein bar (ZonePerfect or Perfect Bar). The nighttime supplement is a protein powder or liquid that can be dissolved in either water or milk.~This is provided to participants with ProCel Vanilla Whey Protein powder which provides 15 grams of protein per serving or the ProCel LiquaCel liquid protein supplement mango, grape, watermelon and/or lemon flavors which provides 16g of protein per serving.
Study NCT04675775 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutrition education handout
Description: A standardized nutrition education handout containing instructions on following a high-protein and sodium restricted diet (depending on the presence of ascites) will be given as part of Standard of Care.
Study NCT05477719 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Wearing of specific compression stockings
Description: The patient will wear specific compression stockings prevent the accumulation of fluids during the day in the lower part of the body and thus limiting the nocturnal drainage effect from the lower part of the body to the upper part of the body
Study NCT05601882 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dupilumab
Description: Subcutaneous Injection
Study NCT06554080 — intervention group
Intervention type: PROCEDURE
Intervention: Platform-switched implant placement
Description: NobelParallel or NobelActive implants placed
Study NCT06554080 — intervention group
Intervention type: PROCEDURE
Intervention: Platform-matched implant placement
Description: Nobel Brånemark, NobelSpeedy Groovy implants placed
Study NCT06280157 — intervention group
Intervention type: BIOLOGICAL
Intervention: GBS-NN/NN2
Description: GBS-NN/NN2 containing 50 μg of GBS-NN and 50 μg of GBS/NN2
Study NCT06563518 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meridol
Description: toothpaste
Study NCT06563518 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colgate Cavity Protection
Description: toothpaste